Objective: This study aimed to retrospectively describe the preliminary single-center clinical experience with obinutuzumab-based combination regimens in the treatment of follicular lymphoma and to analyze the associated treatment efficacy and safety profile. Methods: The efficacy, progression-free survival , and adverse events in 16 FL patients treated with combination regimens containing Obinutuzumab were analyzed retrospectively. Results: Besides the efficacy could not be evaluated in 1 cas...更多
Objective: This study aimed to retrospectively describe the preliminary single-center clinical experience with obinutuzumab-based combination regimens in the treatment of follicular lymphoma and to analyze the associated treatment efficacy and safety profile. Methods: The efficacy, progression-free survival , and adverse events in 16 FL patients treated with combination regimens containing Obinutuzumab were analyzed retrospectively. Results: Besides the efficacy could not be evaluated in 1 case who stopped Obinutuzumab due to adverse events, the overall response rate and complete remission rate of the remaining 15 patients who were treated with combined induction regimen containing Obinutuzumab were 86.7% and 73.3% respectively. At a median follow-up of 27 months, PFS at 1 and 2 years were 87.5% and 68.9% respectively. The most common grade 3~4 hematological adverse events were neutropenia. Anemia and thrombocytopenia were mainly grade 1~2. Peripheral blood lymphocyte subsets analysis showed that CD4T cell count and CD19 B cell count decreased significantly during induction therapy compared with before the treatment [0.181 × 10/L vs. 0.506 × 10/L, u = 4.000, P = 0.043; 0.001 × 10/L vs. 0.084 × 10/L, u = 0.000, P = 0.006], and continued to decrease until 7~12 months of follow-up or maintenance therapy [0.157 × 10/L vs. 0.506 × 10/L, u = 1.000, P = 0.018; 0.001 × 10/L vs. 0.084 × 10/L, u = 0.000, P = 0.008]. The main nonhematological toxicity was infection, with pneumonia being the most common, including 3 cases with COVID-19. Non-hematological toxicity also included infusion-related reactions, liver damage, cardiovascular events, gastro-intestinal reactions, etc., all of which were grade 1~2, and improved after supportive treatment. Conclusion: This preliminary study suggests that obinutuzumab-based regimens may have potential efficacy in FL patients; however, their safety profile, particularly the risk of infection, requires further evaluation in larger-scale studies.收起
